miRNAs及其靶蛋白myostatin在脂肪干细胞治疗骨骼肌运动损伤中的作用机制研究

运动中的肌肉损伤治疗是运动医学中的挑战性问题。在运动损伤后，干细胞治疗具有修复和功能可塑性的潜力，是目前极具前景的治疗方法，但其治疗肌肉损伤的具体机制尚不清楚。肌肉生长抑制素（myostatin，MSTN），可抑制肌细胞分化，促进肌肉萎缩，影响骨骼肌的再生修复，然而脂肪干细胞（ASCs）治疗骨骼肌运动损伤过程中是否通过调节MSTN发挥作用，尚不清楚。miRNAs既参与肌肉再生和分化调控，也参与MSTN的调节，前期研究发现在ASCs治疗骨骼肌运动损伤过程中，MSTN表达显著下调，miRNAs是否通过调节MSTN发挥作用，有待进一步研究。本研究通过检测特异miRNAs及其靶蛋白MSTN的表达，结合ASCs治疗骨骼肌运动损伤修复进程及特异miRNAs功能验证，探讨miRNAs及其靶蛋白MSTN在ASCs治疗骨骼肌运动损伤中的作用，以期为临床上ASCs治疗骨骼肌运动损伤提供新的靶点或思路。

The treatment of muscle injury during exercise is a challenging problem in sports medicine. Stem cell therapy, which has the potential of repair and functional plasticity after athletic injury, is a promising therapeutic method at present. However, the specific mechanism of stem cell therapy for muscle injury is still unclear. Myostatin (MSTN) inhibits myoblast differentiation, promotes muscle atrophy, and affects skeletal muscle regeneration. However, it is unclear whether adipose-derived stem cells (ASCs) play a role by regulating MSTN in the treatment of skeletal muscle athletic injury. MiRNAs not only participates in the regulation of muscle regeneration and differentiation, but also in the regulation of MSTN. Previous studies have found that MSTN expression is significantly down-regulated during ASCs treatment of skeletal muscle athletic injury, and whether miRNAs play a role in regulating MSTN need to be further studied. In this study, we explore the role of miRNAs and their target MSTN in the treatment of skeletal muscle athletic injury. We hope to provide new targets or ideas for the treatment of skeletal muscle athletic injury.